Prevention of hepatitis B virus recurrence after liver transplantation
- 7 November 2006
- journal article
- review article
- Published by Wiley in Clinical Transplantation
- Vol. 20 (s17) , 111-116
Abstract
Abstract: Liver transplantation for hepatitis B virus (HBV)‐related liver disease has changed from a contraindication to outcomes comparable with non‐HBV‐related liver transplantations during the last two decades. Mainly the implementation of immunoprophylaxis with hepatitis B immunoglobulin (HBIG) and the use of nucleoside analogs such as lamivudine and adefovir account for this dramatic change. The standard of care in most centers today consists of lamivudine treatment in replicating hepatitis B pre‐orthotopic liver transplantation (OLT) and a combination regimen of lamivudine and HBIG post‐OLT. With adefovir, a potent antiviral drug became available in recent years that allows for the treatment of patients with lamivudine‐resistant tyrosine‐methionine‐aspartate‐aspartate (YMDD)‐mutant HBV. In the transplantation setting, first studies indicate that a triple prophylactic therapy consisting of lamivudine, adefovir, and HBIG will become the standard of care for YMDD‐mutant‐related hepatitis B. With new drugs emerging for the treatment of chronic HBV, there is optimism for new options also in the transplant setting.Keywords
This publication has 85 references indexed in Scilit:
- Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experienceJournal of Viral Hepatitis, 2006
- Adefovir Dipivoxil Therapy for Lamivudine–Resistant Hepatitis B in Pre- and Post-Liver Transplantation PatientsHepatology, 2003
- Endocytosis of Hepatitis B Immune Globulin into Hepatocytes Inhibits the Secretion of Hepatitis B Virus Surface Antigen and VirionsJournal of Virology, 2003
- Hbv Dna Persistence 10 Years After Liver Transplantation Despite Successful Anti–Hbs Passive ImmunoprophylaxisHepatology, 2003
- A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantationJournal of Hepatology, 2003
- Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation – possible role of mutations in the YMDD motif prior totransplantation as a risk factor for reinfectionJournal of Hepatology, 2001
- Hepatitis B virus surface mutations associated with infection after liver transplantationJournal of Hepatology, 1996
- LONG-TERM FOLLOW-UP OF HEPATITIS B VIRUS-INFECTED RECIPIENTS AFTER ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1994
- Hepatitis B virus reinfection after orthotopic liver transplantationJournal of Hepatology, 1992
- Liver transplantation in HBs antigen (HBsAg) carriersJournal of Hepatology, 1991